Neurocritical Care

, 8:418 | Cite as

Antifibrinolytic Therapy To Prevent Early Rebleeding After Subarachnoid Hemorrhage

  • Mark Chwajol
  • Robert M. Starke
  • Grace H. Kim
  • Stephan A. Mayer
  • E. Sander Connolly
Review Article

Abstract

In the current era of early surgery, there has been little interest in the use of antifibrinolytic therapy to prevent rebleeding after aneurysmal subarachnoid hemorrhage (aSAH). Older studies demonstrated that antifibrinolytics can reduce rebleeding, but long-term therapy results in increased cerebral ischemia from vasospasm, leading to no appreciable effect on mortality. While early surgery would seem to obviate the need for long-term antifibrinolytic use, a subgroup of patients may benefit from early therapy. The rate of pre-operative rebleeding may be as high as 9–17%, causing significant morbidity and mortality. Short-term use of antifibrinolytic agents (less than 3 days) in the presence of calcium channel blocking therapy has shown promising results. A randomized clinical trial of early antifibrinolytic therapy conducted in 2002 showed a significant decrease in rebleeding and a non-significant decrease in overall mortality. In this review, we examine the clinical pharmacology, dosing, monitoring, complications, and side effects of antifibrinolytic treatment. We conclude that early short-term antifibrinolytic therapy might be a reasonable strategy to prevent acute rebleeding and improve long-term outcome in aSAH patients. Additional randomized clinical trials are necessary to determine whether this management strategy is effective.

Keywords

Aminocaproic acid Aneurysm Antifibrinolytics Rebleeding Subarachnoid hemorrhage 

References

  1. 1.
    Hop JW, Rinkel GJ, Algra A, van Gijn J. Quality of life in patients and partners after aneurysmal subarachnoid hemorrhage. Stroke. 1998;29:798–804.PubMedGoogle Scholar
  2. 2.
    Ropper AH, Zervas NT. Outcome 1 year after sah from cerebral aneurysm. Management morbidity, mortality, and functional status in 112 consecutive good-risk patients. J Neurosurg. 1984;60:909–15.PubMedGoogle Scholar
  3. 3.
    Laidlaw JD, Siu KH. Ultra-early surgery for aneurysmal subarachnoid hemorrhage: outcomes for a consecutive series of 391 patients not selected by grade or age. J Neurosurg. 2002;97:250–8; discussion 247–59.PubMedGoogle Scholar
  4. 4.
    Jane JA, Kassell NF, Torner JC, Winn HR. The natural history of aneurysms and arteriovenous malformations. J Neurosurg. 1985;62:321–3.PubMedGoogle Scholar
  5. 5.
    Kassell NF, Torner JC. Aneurysmal rebleeding: a preliminary report from the cooperative aneurysm study. Neurosurgery. 1983;13:479–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL. The international cooperative study on the timing of aneurysm surgery. Part 1: overall management results. J Neurosurg. 1990;73:18–36.PubMedGoogle Scholar
  7. 7.
    Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Koike T, Tanaka R. Ultra-early rebleeding in spontaneous subarachnoid hemorrhage. J Neurosurg. 1996;84:35–42.PubMedGoogle Scholar
  8. 8.
    Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg. 2002;97:771–8.PubMedGoogle Scholar
  9. 9.
    Inagawa T, Kamiya K, Ogasawara H, Yano T. Rebleeding of ruptured intracranial aneurysms in the acute stage. Surg Neurol. 1987;28:93–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenorn J, Eskesen V, Schmidt K, Ronde F. The risk of rebleeding from ruptured intracranial aneurysms. J Neurosurg. 1987;67:329–32.PubMedGoogle Scholar
  11. 11.
    Adams HP Jr, Nibbelink DW, Torner JC, Sahs AL. Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study. Arch Neurol. 1981;38:25–9.PubMedGoogle Scholar
  12. 12.
    Ameen AA, Illingworth R. Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm. J Neurol, Neurosurg Psychiatry. 1981;44:220–6.Google Scholar
  13. 13.
    Hijdra A, van Gijn J, Nagelkerke NJ, Vermeulen M, van Crevel H. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 1988;19:1250–6.PubMedGoogle Scholar
  14. 14.
    Kassell NF, Torner JC, Adams HP Jr. Antifibrinolytic therapy in the acute period following aneurysmal subarachnoid hemorrhage. Preliminary observations from the cooperative aneurysm study. J Neurosurg. 1984;61:225–30.PubMedGoogle Scholar
  15. 15.
    Nibbelink DW, Torner JC, Henderson WG. Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke. 1975;6:622–9.PubMedGoogle Scholar
  16. 16.
    Pinna G, Pasqualin A, Vivenza C, Da Pian R. Rebleeding, ischaemia and hydrocephalus following anti-fibrinolytic treatment for ruptured cerebral aneurysms: a retrospective clinical study. Acta Neurochir. 1988;93:77–87.CrossRefGoogle Scholar
  17. 17.
    Schisano G. The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage. Surg Neurol. 1978;10:217–22.PubMedGoogle Scholar
  18. 18.
    Tovi D. The use of antifibrinolytic drugs to prevent early recurrent aneurysmal subarachnoid haemorrhage. Acta Neurol Scand. 1973;49:163–75.PubMedCrossRefGoogle Scholar
  19. 19.
    Leipzig TJ, Redelman K, Horner TG. Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. J Neurosurg. 1997;86:220–5.PubMedGoogle Scholar
  20. 20.
    Roos Y. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. Star study group. Neurology. 2000;54:77–82.PubMedGoogle Scholar
  21. 21.
    Roos YB, Rinkel GJ, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev (Online). 2005;1:CD000277.Google Scholar
  22. 22.
    Burchiel KJ, Hoffman JM, Bakay RA. Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition. Neurosurgery. 1984;14:57–63.PubMedCrossRefGoogle Scholar
  23. 23.
    Burchiel KJ, Schmer G. A method for monitoring antifibrinolytic therapy in patients with ruptured intracranial aneurysms. J Neurosurg. 1981;54:12–5.PubMedGoogle Scholar
  24. 24.
    Fodstad H, Nilsson IM. Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (amca). Acta Neurochir. 1981;56:25–38.CrossRefGoogle Scholar
  25. 25.
    Fodstad H, Pilbrant A, Schannong M, Stromberg S. Determination of tranexamic acid (amca) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage. Acta Neurochir. 1981;58:1–13.CrossRefGoogle Scholar
  26. 26.
    Beck DW, Adams HP, Flamm ES, Godersky JC, Loftus CM. Combination of aminocaproic acid and nicardipine in treatment of aneurysmal subarachnoid hemorrhage. Stroke. 1988;19:63–7.PubMedGoogle Scholar
  27. 27.
    Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, Disney LB, Khan MI, Grace M, Holness RO et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68:505–17.PubMedGoogle Scholar
  28. 28.
    Stroobandt G, Lambert O, Menard E. The association of tranexamic acid and nimodipine in the pre-operative treatment of ruptured intracranial aneurysms. Acta Neurochir. 1998;140:148–60.CrossRefGoogle Scholar
  29. 29.
    Geronemus R, Herz DA, Shulman K. Streptokinase clot lysis time in patients with ruptured intracranial aneurysms. J Neurosurg. 1974;40:499–503.PubMedGoogle Scholar
  30. 30.
    Sawaya R, Sonnino V, McLaurin RL, Perrotta G. Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of csf fibrin/fibrinogen degradation products. J Neurosurg. 1983;58:699–707.PubMedGoogle Scholar
  31. 31.
    Porter JM, Acinapura AJ, Kapp JP, Silver D. Fibrinolytic activity of the spinal fluid and meninges. Surg Forum. 1966;17:425–7.PubMedGoogle Scholar
  32. 32.
    Levy BJ, Silver D. Treatment of subarachnoid hemorrhage: the ability of epsilon aminocaproic acid to cross the blood brain barrier and reduce the spinal fluid fibrinolytic activity. Surg Forum. 1968;19:413–4.PubMedGoogle Scholar
  33. 33.
    Fodstad H, Forssell A, Liliequist B, Schannong M. Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery. 1981;8:158–65.PubMedCrossRefGoogle Scholar
  34. 34.
    Tovi D, Nilsson IM, Thulin CA. Fibrinolysis and subarachnoid haemorrhage. Inhibitory effect of tranexamic acid. A clinical study. Acta Neurol Scand. 1972;48:393–402.PubMedGoogle Scholar
  35. 35.
    Smith RR, Upchurch JJ. Monitoring antifibrinolytic therapy in subarachnoid hemorrhage. J Neurosurg. 1973;38:339–44.PubMedGoogle Scholar
  36. 36.
    Tovi D, Nilsson IM, Thulin CA. Fibrinolytic activity of the cerebrospinal fluid after subarachnoid haemorrhage. Acta Neurol Scand. 1973;49:1–9.PubMedGoogle Scholar
  37. 37.
    Maurice-Williams RS. Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms? Br Med J. 1978;1:945–7.PubMedGoogle Scholar
  38. 38.
    Uttley AH, Buckell M. Biochemical changes after spontaneous subarachnoid haemorrhage. 3. Coagulation and lysis with special reference to recurrent haemorrhage. J Neurol Neurosurg Psychiatry. 1968;31:621–7.PubMedGoogle Scholar
  39. 39.
    Vermeulen M, van Vliet HH, Lindsay KW, Hijdra A, van Gijn J. Source of fibrin/fibrinogen degradation products in the csf after subarachnoid hemorrhage. J Neurosurg. 1985;63:573–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Nibbelink DW. Antifibrinolytic activity during administration of epsilon-aminocaproic acid. Stroke. 1971;2:555–8.PubMedGoogle Scholar
  41. 41.
    Adams HP Jr, Kassell NF, Torner JC, Nibbelink DW, Sahs AL. Early management of aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study. J Neurosurg. 1981;54:141–5.PubMedGoogle Scholar
  42. 42.
    Vermeij FH, Hasan D, Bijvoet HW, Avezaat CJ. Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage. Stroke. 1998;29:924–30.PubMedGoogle Scholar
  43. 43.
    Starke RM, Kim GH, Fernandez A, Hickman ZL, Ducruet AF, Kellner CP, Hahn DK, Chwajol M, Komotar RJ, Otten M, Mayer SA, Connolly ES. Impact of a policy of early antifibrinolytic therapy for the prevention of acute rebleeding after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39(9).Google Scholar
  44. 44.
    Chandra B. Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Ann Neurol. 1978;3:502–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Kaste M, Ramsay M. Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke. 1979;10:519–22.PubMedGoogle Scholar
  46. 46.
    Tsementzis SA, Hitchcock ER, Meyer CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir 1990;102:1–10.CrossRefGoogle Scholar
  47. 47.
    van Rossum J, Wintzen AR, Endtz LJ, Schoen JH, de Jonge H. Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Ann Neurol 1977;2:238–42.PubMedCrossRefGoogle Scholar
  48. 48.
    Vermeulen M, Lindsay KW, Murray GD, Cheah F, Hijdra A, Muizelaar JP, Schannong M, Teasdale GM, van Crevel H, van Gijn J. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med. 1984;311:432–7.PubMedGoogle Scholar
  49. 49.
    Girvin JP. The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Trans Am Neurol Assoc. 1973;98:150–2.PubMedGoogle Scholar
  50. 50.
    Hillman J, von Essen C, Leszniewski W, Johansson I. Significance of “ultra-early” rebleeding in subarachnoid hemorrhage. J Neurosurg. 1988;68:901–7.PubMedGoogle Scholar
  51. 51.
    Roos YB, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M. Timing of surgery in patients with aneurysmal subarachnoid haemorrhage: rebleeding is still the major cause of poor outcome in neurosurgical units that aim at early surgery. J Neurol Neurosurg Psychiatry. 1997;63:490–3.PubMedGoogle Scholar
  52. 52.
    Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke. 2001;32:1176–80.PubMedGoogle Scholar
  53. 53.
    Chowdhary UM, Sayed K. Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1981;44:810–3.PubMedGoogle Scholar
  54. 54.
    Guidetti B, Spallone A. The role of antifibrinolytic therapy in the preoperative management of recently ruptured intracranial aneurysms. Surg Neurol. 1981;15:239–48.PubMedCrossRefGoogle Scholar
  55. 55.
    Graff-Radford NR, Torner J, Adams HP Jr, Kassell NF. Factors associated with hydrocephalus after subarachnoid hemorrhage. A report of the cooperative aneurysm study. Arch Neurol. 1989;46:744–52.PubMedGoogle Scholar
  56. 56.
    Kenning JA, Heros RC, Dujovny M, Latchaw RE, Nelson D. An experimental study of the influence of antifibrinolytic therapy on post-subarachnoid-hemorrhagic cerebral vasospasm and hydrocephalus. Surg Neurol. 1984;21:159–64.PubMedCrossRefGoogle Scholar
  57. 57.
    Knibestol M, Karadayi A, Tovi D. Echo-encephalographic study of ventricular dilatation after subarachnoid hemorrhage, with special reference to the effect of antifibrinolytic treatment. Acta Neurol Scand. 1976;54:57–70.PubMedCrossRefGoogle Scholar
  58. 58.
    Park BE. Spontaneous subarachnoid hemorrhage complicated by communicating hydrocephalus: epsilon amino caproic acid as a possible predisposing factor. Surg Neurol. 1979;11:73–80.PubMedGoogle Scholar
  59. 59.
    Tsementzis SA, Honan WP, Nightingale S, Hitchcock ER, Meyer CH. Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochir. 1990;103:116–21.CrossRefGoogle Scholar
  60. 60.
    Flamm ES, Adams HP Jr, Beck DW, Pinto RS, Marler JR, Walker MD, Godersky JC, Loftus CM, Biller J, Boarini DJ et al. Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 1988;68:393–400.PubMedCrossRefGoogle Scholar
  61. 61.
    Torner JC, Kassell NF, Wallace RB, Adams HP Jr. Preoperative prognostic factors for rebleeding and survival in aneurysm patients receiving antifibrinolytic therapy: report of the cooperative aneurysm study. Neurosurgery. 1981;9:506–13.PubMedCrossRefGoogle Scholar
  62. 62.
    Gralnick HR, Greipp P. Thrombosis with epsilon aminocaproic acid therapy. Am J Clin Pathol. 1971;56:151–4.PubMedGoogle Scholar
  63. 63.
    Naeye RL. Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocapproic acid. Blood. 1962;19:694–701.PubMedGoogle Scholar
  64. 64.
    Woo KS, Tse LK, Woo JL, Vallance-Owen J. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract. 1989;43:465–6.PubMedGoogle Scholar
  65. 65.
    Gelmers HJ. Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid. Acta Neurochir. 1980;52:45–50.CrossRefGoogle Scholar
  66. 66.
    Sengupta RP, So SC, Villarejo-Ortega FJ. Use of epsilon aminocaproic acid (eaca) in the preoperative management of ruptured intracranial aneurysms. J Neurosurg. 1976;44:479–84.PubMedGoogle Scholar
  67. 67.
    Fodstad H, Liliequist B, Schannong M, Thulin CA. Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surg Neurol. 1978;10:9–15.PubMedGoogle Scholar
  68. 68.
    Pakarinen S. Incidence, aetiology, and prognosis of primary subarachnoid haemorrhage. A study based on 589 cases diagnosed in a defined urban population during a defined period. Acta Neurol Scand. 1967;43(Suppl 29):21–8.Google Scholar
  69. 69.
    Charytan C, Purtilo D. Glomerular capillary thrombosis and acute renal failure after epsilon-amino caproic acid therapy. N Engl J Med. 1969;280:1102–4.PubMedGoogle Scholar
  70. 70.
    Tubbs RR, Benjamin SP, Dohn DE. Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. J Neurosurg. 1979;51:94–7.PubMedGoogle Scholar
  71. 71.
    Hoffman EP, Koo AH. Cerebral thrombosis associated with amicar therapy. Radiology. 1979;131:687–9.PubMedGoogle Scholar
  72. 72.
    Rydin E, Lundberg PO. Letter: tranexamic acid and intracranial thrombosis. Lancet. 1976;2:49.PubMedCrossRefGoogle Scholar
  73. 73.
    Sonntag VK, Stein BM. Arteriopathic complications during treatment of subarachnoid hemorrhage with epsilon-aminocaproic acid. J Neurosurg. 1974;40:480–5.PubMedGoogle Scholar
  74. 74.
    Scott RM, Garrido E. Spontaneous thrombosis of an intracranial aneurysm during treatment with epsilon aminocaproic acid. Surgical Neurol. 1977;7:21–3.Google Scholar
  75. 75.
    Bennett JR. Myopathy from e-aminocaproic acid: a second case. Postgrad Med J. 1972;48:440–2.PubMedGoogle Scholar
  76. 76.
    Biswas CK, Milligan DA, Agte SD, Kenward DH, Tilley PJ. Acute renal failure and myopathy after treatment with aminocaproic acid. Br Med J. 1980;281:115–6.PubMedGoogle Scholar
  77. 77.
    Britt CW Jr, Light RR, Peters BH, Schochet SS Jr. Rhabdomyolysis during treatment with epsilon-aminocaproic acid. Arch Neurol. 1980;37:187–8.PubMedGoogle Scholar
  78. 78.
    Brodkin HM. Myoglobinuria following epsilon-aminocaproic acid (eaca) therapy. Case report. J Neurosurg. 1980;53:690–2.PubMedCrossRefGoogle Scholar
  79. 79.
    Brown JA, Wollmann RL, Mullan S. Myopathy induced by epsilon-aminocaproic acid. Case report. J Neurosurg. 1982;57:130–4.PubMedCrossRefGoogle Scholar
  80. 80.
    Galassi G, Gibertoni M, Corradini L, Colombo A. Why may epsilon-aminocaproic acid (eaca) induce myopathy in man? Report of a case and literature review. Ital J Neurol Sci. 1983;4:489–92.PubMedCrossRefGoogle Scholar
  81. 81.
    Kennard C, Swash M, Henson RA. Myopathy due to epsilon amino-caproic acid. Muscle Nerve. 1980;3:202–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Lane RJ, McLelland NJ, Martin AM, Mastaglia FL. Epsilon aminocaproic acid (eaca) myopathy. Postgrad Med J. 1979;55:282–5.PubMedGoogle Scholar
  83. 83.
    MacKay AR, Sang UH, Weinstein PR. Myopathy associated with epsilon-aminocaproic acid (eaca) therapy. Report of two cases. J Neurosurg. 1978;49:597–601.PubMedGoogle Scholar
  84. 84.
    Vanneste JA, van Wijngaarden GK. Epsilon-aminocaproic acid myopathy. Report of a case and literature review. Eur Neurol. 1982;21:242–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Glick R, Green D, Ts’ao C, Witt WA, Yu AT, Raimondi AJ. High does epsilon-aminocaproic acid prolongs the bleeding time and increases rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage. Neurosurgery. 1981;9:398–401.PubMedCrossRefGoogle Scholar
  86. 86.
    Wysenbeek AJ, Sella A, Blum I, Yeshurun D. Acute delirious state after epsilon-amino caproic acid administration. Clin Toxicol. 1979;14:93–5.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Mark Chwajol
    • 1
  • Robert M. Starke
    • 2
  • Grace H. Kim
    • 2
  • Stephan A. Mayer
    • 2
    • 3
  • E. Sander Connolly
    • 2
  1. 1.Department of NeurosurgeryAlbert Einstein College of MedicineBronxUSA
  2. 2.Department of Neurological SurgeryColumbia UniversityNew YorkUSA
  3. 3.Departments of NeurologyColumbia UniversityNew YorkUSA

Personalised recommendations